Large doses of methylcobalamin for neurogenic muscular atrophies

Large doses of methylcobalamin for neurogenic muscular atrophies - Methylcobalamin for neurogenic muscular atrophies

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009359

Enrollment

Registered

2012-11-19

Start date

2008-01-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neurogenic muscular atrophy

Interventions

methylcobalamin 25mg/day (Day 1-10) methylcobalamin 25mg/day, every 4 weeks, 5 cycles

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with amyotrophy 2) Written informed consent 3) Outpatient

Exclusion criteria

Exclusion criteria: 1) Patients with critical illness 2) Pregnant or lactating woman 3) Within 3 months from other clinical trial 4) Patients who are not appropriate to participate to the trial.

Design outcomes

Primary

Measure	Time frame
Manual Muscle Testing	—

Secondary

Measure	Time frame
Overall Neuropathy Limitations Scale Subjective symptom Grip strength Nerve conduction study Laboratory data	—

Countries

Japan

Contacts

Public ContactSonoko Misawa

Chiba University Graduate School of Medicine Department of Neurology

sonoko.m@mb.infoweb.ne.jp043-226-2126

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026